Athenex to acquire Kuur to develop cell therapies

By The Science Advisory Board staff writers

May 5, 2021 -- Athenex plans to acquire Kurr Therapeutics, including its allogeneic chimeric antigen receptor-natural killer T (CAR-NKT) cell platform, to expand its cell therapy development.

Kurr's platform aids in the development immunotherapies‌ ‌for‌ ‌the‌ ‌treatment‌ ‌of‌ ‌solid‌ ‌and‌ ‌hematological‌ ‌malignancies.‌ ‌

Athenex will pay $70 million upfront to Kurr shareholders, as well as some employees and directors. Additionally,‌ ‌they‌ ‌are‌ ‌eligible‌ ‌to‌ ‌receive‌ ‌up‌ ‌to‌ ‌$115‌ ‌million‌ ‌in‌ ‌milestone‌ ‌payments. Milestone payments of cash, common stock, or combination would be made at Athenex's sole discretion.


Copyright © 2021 scienceboard.net
 


MemberID or email address:

Password:
Forgot your password?